The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States.
 
Shaji Kumar
Honoraria - Dr. Reddy's
Consulting or Advisory Role - Abbvie (Inst); Abbvie (Inst); Adaptive Biotechnologies; Amgen (Inst); Celgene (Inst); Genecentrix; Genentech/Roche (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); Merck (Inst); Oncopeptides; Takeda (Inst)
Research Funding - Abbvie (Inst); Celgene (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst)
 
Istvan Majer
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Sumeet Panjabi
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Jean Malacan
Employment - Amgen
 
Rohan Medhekar
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Marco Campioni
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Meletios A. Dimopoulos
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Takeda